Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and
pilot efficacy of multiple ascending dose levels of AKB-9778 given as subcutaneous injections
daily for 28 days in patients with diabetic macular edema (DME).